查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2094031

全球標靶蛋白分解市場：依治療方式、標靶蛋白、適應症、研發階段和最終用戶分類－市場規模、產業動態、機會分析和預測（2026-2035 年）

Global Targeted Protein Degradation Market By Modality, Target Protein, Indication, Development Stage, End User - Market Size, Industry Dynamics, Opportunity Analysis and Forecast For 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 220 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球標靶蛋白分解（TPD）市場預計在預測期內將經歷顯著成長，市場規模將從2025年的約6.908億美元成長到2035年的約50.49億美元。在蛋白分解技術的快速發展、製藥業投資的增加以及對創新療法的需求不斷成長的推動下，該市場預計將在2026年至2035年間保持21.9%的高複合年成長率。

市場成長的主要驅動力是新一代分解平台的進步，特別是PROTAC（蛋白質靶向嵌合體）和分子膠。這些技術為藥物研發帶來了新的範式，使其從傳統的基於抑制的方法轉向選擇性地去除致病蛋白。生物技術公司、製藥公司和研究機構的大量投資進一步加速了市場發展。各公司正在拓展其臨床研發管線，建立策略聯盟，並開發專有的分解平台，以提高標靶選擇性、治療效果和安全性。

顯著的市場趨勢

全球標靶蛋白分解 (TPD) 市場競爭異常激烈，生物技術公司和大型製藥企業都在積極探索創新的分解平台，拓展臨床研發管線，並將產品應用於腫瘤學、免疫學及其他治療領域。 Arvinas 被公認為靶向蛋白分解領域的先驅和最具影響力的公司之一，並擁有業內最先進的臨床研發管線之一。

Chimera Therapeutics透過將其蛋白水解技術的應用範圍從傳統腫瘤學到免疫學和發炎性疾病，在靶向蛋白水解（TPD）市場確立了穩固的地位。百時美施貴寶透過收購Celgene，獲得了重要的蛋白水解資產和專業技術，從而成為靶向蛋白水解領域的主要參與者。

C4 Therapeutics專注於開發旨在消除致病蛋白的新一代PROTAC技術。 Nurix Therapeutics是另一個標靶蛋白水解市場的領導企業，專門從事新型雙功能蛋白水解劑及相關蛋白水解技術的開發。該公司致力於開發針對疾病相關蛋白的療法，尤其是在腫瘤和骨髓惡性腫瘤（例如B細胞癌）領域。

關鍵成長要素

腫瘤學和精準醫療正在推動成長要素。日益加重的全球惡性腫瘤負擔正在加速對創新療法的投資，以期克服傳統癌症療法的限制。靶向蛋白水解作為一種極具前景的精準腫瘤學策略，正逐漸嶄露頭角，因為它採用了一種截然不同的作用機制——選擇性地去除疾病相關蛋白，而非僅僅抑制其活性。

新機會的趨勢

「分子黏合劑」的興起為全球標靶蛋白水解市場帶來了重要的全新機遇，這主要得益於業界對更簡單、更有效率且可能具有藥物樣特性的分解方法的日益成長的興趣。雖然protacs和其他雙功能分解劑已透過展現其選擇性去除疾病相關蛋白的能力奠定了靶向蛋白水解的基礎，但分子膠作為一種能夠克服大型分解劑分子結構和藥物動力學局限性的新一代療法，正吸引著人們的注意。它們獨特的作用機制和簡化的分子結構，為拓展可進行治療標靶的蛋白質範圍創造了新的機會。

最佳化障礙

藥物動力學的複雜性是限制全球標靶蛋白分解市場成長的一大挑戰，尤其是在PROTACs和其他雙功能分子等先進分解方式方面。儘管這些技術有望透過選擇性去除蛋白質來開發突破性的治療方法，但與傳統的小分子療法相比，其相對複雜的分子結構為藥物研發帶來了顯著挑戰。分解誘導分子的分子尺寸增加、分子量增加以及化學組成複雜，會對溶解度、吸收、分佈、代謝和排泄等關鍵藥物動力學特性產生負面影響，可能會限制其臨床應用和商業性化推廣。

目錄

第1章執行摘要：全球靶向蛋白質分解市場

第2章：調查方法與研究框架

  • 研究目標
  • 產品概述
  • 市場區隔
  • 定性研究
    • 一手和二手資訊
  • 量化研究
    • 一手和二手資訊
  • 主要調查受訪者組成：按地區分類
  • 本研究的前提
  • 市場規模估算
  • 數據三角測量

第3章：全球標靶蛋白分解市場概覽

  • 產業價值鏈分析
  • 產業展望
    • 全球標靶蛋白質分解（TPD）產業概覽
    • PROTAC、分子黏合劑及其在腫瘤學之外的應用，以及在「藥物挑戰性」蛋白質組中的應用。
    • Degrader 與大型製藥企業達成協議，開發新型 E3 連接酶，並利用人工智慧進行藥物發現。
  • PESTLE分析
  • 波特五力分析
  • 市場成長及前景
    • 2020-2035年市場收入估算與預測
    • 價格趨勢分析：依模式分類

第4章：全球標靶蛋白分解市場分析

  • 競爭對手儀錶板
    • 市場集中度
    • 企業市場占有率分析，2025 年
    • 競爭對手分析與基準測試

第5章：全球標靶蛋白分解市場分析

  • 市場動態和趨勢
    • 成長要素
    • 抑制因子
    • 機會
    • 主要趨勢
  • 市場規模及預測，2020-2035年
    • 按模式
      • 關鍵見解
        • PROTACs/雙功能分解劑
        • 分子膠
        • 其他[LYTACs、AUTACs]
    • 透過標靶蛋白
      • 關鍵見解
        • 轉錄因子
        • 激酶
        • 核受體
        • 支架蛋白
    • 適應症
      • 關鍵見解
        • 腫瘤學
        • 免疫學和炎症
        • 神經退化性疾病
        • 其他
    • 按發展階段
      • 關鍵見解
        • 臨床前階段
        • 臨床階段
        • 已通過核准的
    • 最終用戶
      • 關鍵見解
        • 生物製藥
        • 學術和研究
        • CRO
    • 按地區
      • 關鍵見解
        • 北美洲
          • 美國
          • 加拿大
          • 墨西哥
        • 歐洲
          • 西歐
            • 英國
            • 德國
            • 法國
            • 義大利
            • 西班牙
            • 其他西歐國家
          • 東歐
            • 波蘭
            • 俄羅斯
            • 其他東歐國家
        • 亞太地區
          • 中國
          • 印度
          • 日本
          • 澳洲和紐西蘭
          • 韓國
          • ASEAN
          • 其他亞太國家
        • 中東和非洲（MEA）
          • 沙烏地阿拉伯
          • 南非
          • UAE
          • 其他中東和非洲國家
        • 南美洲
          • 阿根廷
          • 巴西
          • 其他南美國家

第6章：北美市場分析

第7章：歐洲市場分析

第8章：亞太市場分析

第9章：中東和非洲市場分析

第10章：南美市場分析

第11章：公司簡介

  • Bio-Techne
  • Bayer AG
  • BroadPharm
  • BPS Bioscience, Inc.
  • MedChemExpress
  • LifeSensors Inc
  • Promega Corporation
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Other Prominent Players

第12章附錄

簡介目錄
Product Code: AA07261884

The global targeted protein degradation (TPD) market is projected to experience substantial growth over the forecast period, expanding from an estimated valuation of USD 690.8 million in 2025 to approximately USD 5,004.9 million by 2035. The market is expected to register a strong compound annual growth rate (CAGR) of 21.9% between 2026 and 2035, driven by rapid advancements in protein degradation technologies, increasing pharmaceutical investment, and growing demand for innovative therapeutic approaches.

A primary factor driving market growth is the advancement of next-generation degradation platforms, particularly PROTACs (proteolysis-targeting chimeras) and molecular glues. These technologies have introduced a new paradigm in pharmaceutical development by shifting from traditional inhibition-based approaches toward selective removal of disease-causing proteins. Significant investment from biotechnology companies, pharmaceutical organizations, and research institutions is further accelerating market development. Companies are expanding clinical pipelines, forming strategic collaborations, and advancing proprietary degradation platforms to improve target selectivity, therapeutic potency, and safety profiles.

Noteworthy Market Developments

The global targeted protein degradation (TPD) market is characterized by strong competition among biotechnology companies and pharmaceutical leaders that are advancing innovative degradation platforms, expanding clinical pipelines, and exploring applications across oncology, immunology, and other therapeutic areas. Arvinas is widely recognized as one of the pioneers and most influential companies in the targeted protein degradation field, with one of the most advanced clinical pipelines in the industry.

Kymera Therapeutics has established a strong position in the TPD market by expanding the application of degradation technologies beyond traditional oncology indications into immunology and inflammatory diseases. Bristol Myers Squibb has become a significant participant in the targeted protein degradation landscape through its acquisition of Celgene, which provided access to important protein degradation assets and expertise.

C4 Therapeutics focuses on advancing next-generation PROTAC technologies designed to eliminate disease-causing proteins. Nurix Therapeutics is another key player in the targeted protein degradation market, specializing in the development of novel bifunctional degraders and related degradation technologies. The company focuses on creating therapies that target disease-associated proteins, particularly within oncology and hematological malignancies such as B-cell cancers.

Core Growth Drivers

Oncology and precision medicine represent major growth drivers for the global targeted protein degradation (TPD) market, supported by the increasing prevalence of cancer and the urgent need for more effective therapies capable of addressing treatment resistance. The growing burden of malignant diseases worldwide has accelerated investment in innovative therapeutic approaches that can overcome the limitations of conventional cancer treatments. Targeted protein degradation has emerged as a promising strategy within precision oncology because it introduces a fundamentally different mechanism of action by selectively eliminating disease-associated proteins rather than simply inhibiting their activity.

Emerging Opportunity Trends

The rise of molecular glues represents a significant emerging opportunity trend within the global targeted protein degradation market, driven by increasing industry interest in simpler, more efficient, and potentially more drug-like degradation approaches. While PROTACs and other bifunctional degraders have established the foundation of targeted protein degradation by demonstrating the ability to selectively eliminate disease-associated proteins, molecular glues are gaining attention as a next-generation modality that may overcome several structural and pharmacokinetic limitations associated with larger degrader molecules. Their unique mechanism and simplified molecular architecture are creating new opportunities for expanding the range of proteins that can be therapeutically targeted.

Barriers to Optimization

Pharmacokinetic complexity represents a significant challenge that may restrain the growth of the global targeted protein degradation market, particularly for advanced degrader modalities such as PROTACs and other bifunctional molecules. Although these technologies offer transformative therapeutic potential through selective protein elimination, their relatively complex molecular structures create substantial drug development challenges compared with conventional small-molecule therapies. The larger molecular size, increased molecular weight, and intricate chemical composition of degrader molecules can negatively influence key pharmacokinetic properties, including solubility, absorption, distribution, metabolism, and elimination, potentially limiting their clinical translation and commercial adoption.

Detailed Market Segmentation

By Modality, PROTACs (proteolysis-targeting chimeras) and bifunctional degraders accounted for the largest share of the global targeted protein degradation market in 2025, driven by their distinctive event-driven pharmacological mechanism and broad therapeutic potential. These advanced degradation platforms have emerged as the leading modality within the targeted protein degradation landscape because they offer a fundamentally different approach from conventional small-molecule therapies. Rather than continuously occupying and blocking the active site of a disease-associated protein, PROTACs are designed to induce selective protein elimination by directing targeted proteins toward the cell's natural degradation machinery. This mechanism enables a more efficient and durable therapeutic response, positioning PROTACs as a transformative technology in precision medicine.

By Target Protein, transcription factors represent one of the fastest-growing and most promising frontiers within the global targeted protein degradation market, driven by the increasing ability of advanced degradation technologies to address previously considered "undruggable" protein targets. Historically, transcription factors have been among the most challenging therapeutic targets due to their lack of well-defined binding pockets and their involvement in complex protein-DNA interactions. Conventional small-molecule inhibitors have often struggled to effectively modulate these proteins because of their large, flat interaction surfaces and dynamic cellular functions. Targeted protein degradation technologies are changing this paradigm by enabling selective elimination of transcription factors rather than attempting to directly inhibit their activity.

By Indication, oncology accounted for the largest share of the global targeted protein degradation market in 2025, maintaining a dominant position due to the significant unmet medical need for innovative cancer therapies capable of addressing treatment resistance and improving patient outcomes. The oncology segment continues to represent the primary focus area for targeted protein degradation research because many cancer-driving proteins have historically been considered difficult or impossible to target using conventional therapeutic approaches. By introducing a fundamentally different mechanism of action, targeted protein degradation technologies offer the potential to eliminate disease-causing proteins rather than merely inhibit their activity, creating new opportunities for treating complex and resistant malignancies.

By Development Stage, the preclinical segment represents the foundational backbone of the global targeted protein degradation market, reflecting an intense phase of scientific innovation, technology refinement, and pipeline expansion. Although clinical-stage candidates attract significant attention due to their potential therapeutic breakthroughs and commercialization prospects, the extensive volume of preclinical research programs ultimately determines the long-term direction and growth potential of the market. The increasing number of early-stage discovery initiatives demonstrates strong confidence among biotechnology companies, pharmaceutical organizations, and academic researchers in the ability of targeted protein degradation technologies to address previously challenging disease targets.

Segment Breakdown

By Modality

  • PROTACs/Bifunctional Degraders
  • Molecular Glues
  • Other [LYTACs, AUTACs]

By Target Protein

  • Transcription Factors
  • Kinases
  • Nuclear Receptors
  • Scaffolding Proteins

By Indication

  • Oncology
  • Immunology & Inflammation
  • Neurodegeneration
  • Others

By Development Stage

  • Preclinical
  • Clinical
  • Approved

By End User

  • Biopharma
  • Academic & Research
  • CROs

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • In 2025, North America secured the leading position in the global targeted protein degradation market, supported by substantial venture capital investments, a rapidly expanding biotechnology ecosystem, and a strong pipeline of clinical-stage degradation therapies. The region's dominance is primarily driven by the United States, which serves as the central hub for innovation, research, commercialization, and drug development activities within the targeted protein degradation landscape.
  • The United States contributes more than 75% of North America's targeted protein degradation market revenue, reflecting its strong position in both scientific discovery and commercial translation. Biotechnology companies operating within major innovation hubs benefit from extensive collaborations with leading academic institutions, research organizations, and pharmaceutical partners, enabling rapid advancement of first-in-class protein degradation technologies, including PROTACs (proteolysis-targeting chimeras) and other next-generation targeted degradation approaches.
  • Massachusetts and California remain particularly influential centers for targeted protein degradation innovation due to their dense concentration of biotechnology companies, academic research facilities, and pharmaceutical development capabilities. These ecosystems support continuous innovation by enabling close interaction between basic science researchers, medicinal chemists, computational biologists, and clinical development teams.

Leading Market Participants

  • Bio-Techne
  • Bayer AG
  • BroadPharm
  • BPS Bioscience, Inc.
  • MedChemExpress
  • LifeSensors Inc
  • Promega Corporation
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Targeted Protein Degradation Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global Targeted Protein Degradation Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. E3 Ligase Ligand, Building-Block & Reagent Suppliers
    • 3.1.2. Degrader Discovery Platform & AI-Driven Design Providers
    • 3.1.3. Biopharma Developers & Preclinical / Clinical Programs
    • 3.1.4. CRO, CDMO & Manufacturing Partners
    • 3.1.5. End Users (Biopharma, Academic & Research, CROs)
  • 3.2. Industry Outlook
    • 3.2.1. Overview of the Global Targeted Protein Degradation (TPD) Industry
    • 3.2.2. PROTACs, Molecular Glues & Expansion Beyond Oncology into the 'Undruggable' Proteome
    • 3.2.3. Big-Pharma Licensing Deals, Novel E3 Ligases & AI-Enabled Degrader Discovery
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis, By Modality

Chapter 4. Global Targeted Protein Degradation Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Targeted Protein Degradation Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Modality
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. PROTACs/Bifunctional Degraders
        • 5.2.1.1.2. Molecular Glues
        • 5.2.1.1.3. Other [LYTACs, AUTACs]
    • 5.2.2. By Target Protein
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Transcription Factors
        • 5.2.2.1.2. Kinases
        • 5.2.2.1.3. Nuclear Receptors
        • 5.2.2.1.4. Scaffolding Proteins
    • 5.2.3. By Indication
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Oncology
        • 5.2.3.1.2. Immunology & Inflammation
        • 5.2.3.1.3. Neurodegeneration
        • 5.2.3.1.4. Others
    • 5.2.4. By Development Stage
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Preclinical
        • 5.2.4.1.2. Clinical
        • 5.2.4.1.3. Approved
    • 5.2.5. By End User
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. Biopharma
        • 5.2.5.1.2. Academic & Research
        • 5.2.5.1.3. CROs
    • 5.2.6. By Region
      • 5.2.6.1. Key Insights
        • 5.2.6.1.1. North America
          • 5.2.6.1.1.1. The U.S.
          • 5.2.6.1.1.2. Canada
          • 5.2.6.1.1.3. Mexico
        • 5.2.6.1.2. Europe
          • 5.2.6.1.2.1. Western Europe
            • 5.2.6.1.2.1.1. The UK
            • 5.2.6.1.2.1.2. Germany
            • 5.2.6.1.2.1.3. France
            • 5.2.6.1.2.1.4. Italy
            • 5.2.6.1.2.1.5. Spain
            • 5.2.6.1.2.1.6. Rest of Western Europe
          • 5.2.6.1.2.2. Eastern Europe
            • 5.2.6.1.2.2.1. Poland
            • 5.2.6.1.2.2.2. Russia
            • 5.2.6.1.2.2.3. Rest of Eastern Europe
        • 5.2.6.1.3. Asia Pacific
          • 5.2.6.1.3.1. China
          • 5.2.6.1.3.2. India
          • 5.2.6.1.3.3. Japan
          • 5.2.6.1.3.4. Australia & New Zealand
          • 5.2.6.1.3.5. South Korea
          • 5.2.6.1.3.6. ASEAN
          • 5.2.6.1.3.7. Rest of Asia Pacific
        • 5.2.6.1.4. Middle East & Africa (MEA)
          • 5.2.6.1.4.1. Saudi Arabia
          • 5.2.6.1.4.2. South Africa
          • 5.2.6.1.4.3. UAE
          • 5.2.6.1.4.4. Rest of MEA
        • 5.2.6.1.5. South America
          • 5.2.6.1.5.1. Argentina
          • 5.2.6.1.5.2. Brazil
          • 5.2.6.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Modality
      • 6.2.1.2. By Target Protein
      • 6.2.1.3. By Indication
      • 6.2.1.4. By Development Stage
      • 6.2.1.5. By End User
      • 6.2.1.6. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Modality
      • 7.2.1.2. By Target Protein
      • 7.2.1.3. By Indication
      • 7.2.1.4. By Development Stage
      • 7.2.1.5. By End User
      • 7.2.1.6. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Modality
      • 8.2.1.2. By Target Protein
      • 8.2.1.3. By Indication
      • 8.2.1.4. By Development Stage
      • 8.2.1.5. By End User
      • 8.2.1.6. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Modality
      • 9.2.1.2. By Target Protein
      • 9.2.1.3. By Indication
      • 9.2.1.4. By Development Stage
      • 9.2.1.5. By End User
      • 9.2.1.6. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Modality
      • 10.2.1.2. By Target Protein
      • 10.2.1.3. By Indication
      • 10.2.1.4. By Development Stage
      • 10.2.1.5. By End User
      • 10.2.1.6. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Bio-Techne
  • 11.2. Bayer AG
  • 11.3. BroadPharm
  • 11.4. BPS Bioscience, Inc.
  • 11.5. MedChemExpress
  • 11.6. LifeSensors Inc
  • 11.7. Promega Corporation
  • 11.8. Merck KGaA
  • 11.9. Thermo Fisher Scientific, Inc.
  • 11.10. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators